Last update 05 Mar 2026

Acerand Therapeutics (Shanghai) Co., Ltd.

Subsidiary Company|2020|Shanghai Shi, China|
acerand.com

Overview

Tags

Neoplasms
Urogenital Diseases
Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms3
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
SOS1(Son of sevenless homolog 1)1
PARP1(Poly (ADP-Ribose) polymerase 1)1
CYP11A1(Cytochrome P450 11A1)1

Related

3
Drugs associated with Acerand Therapeutics (Shanghai) Co., Ltd.
ACE-86225106
Target
PARP1
Mechanism
PARP1 inhibitors
Active Org.
Acerand Therapeutics (Shanghai) Co., Ltd.
Originator Org.
Acerand Therapeutics (Shanghai) Co., Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+2]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
ACE-232
Target
CYP11A1
Mechanism
CYP11A1 inhibitors
Active Org.
Acerand Therapeutics (Shanghai) Co., Ltd. [+1]
Originator Org.
Acerand Therapeutics (Hong Kong) Ltd.
Active Indication
Adenocarcinoma of prostate [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
ACE-47228211
Target
SOS1
Mechanism
SOS1 inhibitors
Active Org.
Acerand Therapeutics (Shanghai) Co., Ltd.
Originator Org.
Acerand Therapeutics (USA) Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Acerand Therapeutics (Shanghai) Co., Ltd.
NCT06801236
/ RecruitingPhase 1
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)
NCT06380660
/ RecruitingPhase 1/2
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
100 Clinical Results associated with Acerand Therapeutics (Shanghai) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Acerand Therapeutics (Shanghai) Co., Ltd.
Login to view more data
100 Deals associated with Acerand Therapeutics (Shanghai) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Acerand Therapeutics (Shanghai) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
1
IND Approval
Phase 1
1
1
Phase 2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free